Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18669396 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL23647304 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15754779 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL19742389 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18669395 | 0.96 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2 | |
| SCHEMBL22638684 | 0.96 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2 | |
| SCHEMBL28605474 | 0.96 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18669952 | 0.87 | CNR1 (0.40) | ALDH1A1CNR1CNR2 | |
| SCHEMBL31213151 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18954218 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582611-B2 | Lipid nanoparticle compositions and uses thereof | RECODE THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12553042-B2 | Method for quantifying an amount of capped messenger RNA | RECODE THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025160177-A9 | COMPOSITIONS AND METHODS FOR ORGAN AND CELL TARGETED DELIVERY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4630057-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | Recode Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250288688-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12364773-B2 | Lipid nanoparticle compositions and uses thereof | RECODE THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025137646-A1 | GENE EDITING METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | RECODE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12337068-B2 | Lipid nanoparticle compositions and uses thereof | RECODE THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250188440-A1 | METHOD FOR QUANTIFYING AN AMOUNT OF CAPPED MESSENGER RNA | RECODE THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250177562-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025046121-A1 | LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO AND IONIZABLE LIPID | NOVOARC GMBH (AT) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025029927-A1 | LIPID NANOPARTICLE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250032424-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2025024814-A2 | TRANSMEMBRANE RECEPTOR GENE EDITING | ORTHOBIO THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12133923-B2 | Lipid nanoparticle compositions and uses thereof | RECODE THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024123633-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553042-B2 | Method for quantifying an amount of capped messenger RNA | RNGTT, RNMT, FBL | ALDH1A1 4550/4885CNR1 4839/4885CNR2 4836/4885 |
| US-12133923-B2 | Lipid nanoparticle compositions and uses thereof | LIPA, NPC1L1, NPC1 | ALDH1A1 3082/4885CNR1 2897/4885CNR2 3697/4885 |
| US-20250288688-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, AUP1, PLIN3 | ALDH1A1 1210/4885CNR1 1118/4885CNR2 1174/4885 |
| US-12364773-B2 | Lipid nanoparticle compositions and uses thereof | LIPA, AUP1, PLIN3 | ALDH1A1 1210/4885CNR1 1118/4885CNR2 1174/4885 |
| US-20250177562-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, AUP1, PLIN3 | ALDH1A1 1210/4885CNR1 1118/4885CNR2 1174/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | ALDH1A1 3082/4885CNR1 2897/4885CNR2 3697/4885 |
| US-12337068-B2 | Lipid nanoparticle compositions and uses thereof | LIPA, NPC1L1, NPC1 | ALDH1A1 3082/4885CNR1 2897/4885CNR2 3697/4885 |
| US-20250032424-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | ALDH1A1 3082/4885CNR1 2897/4885CNR2 3697/4885 |
| US-12582611-B2 | Lipid nanoparticle compositions and uses thereof | CFTR, CETP, STARD3 | ALDH1A1 3837/4885CNR1 2569/4885CNR2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.